Literature DB >> 21036951

Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions.

Eleanor J Guest1, Leon Aarons, J Brian Houston, Amin Rostami-Hodjegan, Aleksandra Galetin.   

Abstract

Current assessment of drug-drug interaction (DDI) prediction success is based on whether predictions fall within a two-fold range of the observed data. This strategy results in a potential bias toward successful prediction at lower interaction levels [ratio of the area under the concentration-time profile (AUC) in the presence of inhibitor/inducer compared with control is <2]. This scenario can bias any assessment of different DDI prediction algorithms if databases contain large proportion of interactions in this lower range. Therefore, the current study proposes an alternative method to assess prediction success with a variable prediction margin dependent on the particular AUC ratio. The method is applicable for assessment of both induction and inhibition-related algorithms. The inclusion of variability into this predictive measure is also considered using midazolam as a case study. Comparison of the traditional two-fold and the new predictive method was performed on a subset of midazolam DDIs collated from previous databases; in each case, DDIs were predicted using the dynamic model in Simcyp simulator. A 21% reduction in prediction accuracy was evident using the new predictive measure, in particular at the level of no/weak interaction (AUC ratio <2). However, inclusion of variability increased the prediction success at these levels by two-fold. The trend of lower prediction accuracy at higher potency of DDIs reported in previous studies is no longer apparent when predictions are assessed via the new predictive measure. Thus, the study proposes a more logical method for the assessment of prediction success and its application for induction and inhibition DDIs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036951     DOI: 10.1124/dmd.110.036103

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  55 in total

1.  Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.

Authors:  Jane R Kenny; Sophie Mukadam; Chenghong Zhang; Suzanne Tay; Carol Collins; Aleksandra Galetin; S Cyrus Khojasteh
Journal:  Pharm Res       Date:  2012-03-14       Impact factor: 4.200

2.  Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration.

Authors:  Christian Wagner; Yuzhuo Pan; Vicky Hsu; Joseph A Grillo; Lei Zhang; Kellie S Reynolds; Vikram Sinha; Ping Zhao
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

3.  Pediatric Development of Bosentan Facilitated by Modeling and Simulation.

Authors:  Jochen Zisowsky; Martine Géhin; Andjela Kusic-Pajic; Andreas Krause; Maurice Beghetti; Jasper Dingemanse
Journal:  Paediatr Drugs       Date:  2017-04       Impact factor: 3.022

4.  A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.

Authors:  Daniel Moj; Hugo Maas; André Schaeftlein; Nina Hanke; José David Gómez-Mantilla; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

5.  Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug-Drug Interactions Involving Enzyme Modulation.

Authors:  Chia-Hsiang Hsueh; Vicky Hsu; Yuzhuo Pan; Ping Zhao
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

6.  Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.

Authors:  Cyrus Ghobadi; Trevor N Johnson; Mohsen Aarabi; Lisa M Almond; Aurel Constant Allabi; Karen Rowland-Yeo; Masoud Jamei; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

7.  Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.

Authors:  Sumit Bhatnagar; Dwaipayan Mukherjee; Ahmed Hamed Salem; Dale Miles; Rajeev M Menon; John P Gibbs
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-04       Impact factor: 3.333

8.  Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.

Authors:  Weize Huang; Mariko Nakano; Jennifer Sager; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2017-08-31       Impact factor: 3.922

9.  Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA.

Authors:  Christian Wagner; Yuzhuo Pan; Vicky Hsu; Vikram Sinha; Ping Zhao
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

Review 10.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.